Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nang Kuang Pharmaceutical Co Ltd
Income from Continuing Operations
Nang Kuang Pharmaceutical Co Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
Nang Kuang Pharmaceutical Co Ltd
TWSE:1752
|
Income from Continuing Operations
NT$243.9m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Income from Continuing Operations
NT$1B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Income from Continuing Operations
NT$137m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-14%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Income from Continuing Operations
NT$4.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
36%
|
CAGR 10-Years
40%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Income from Continuing Operations
NT$1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
C
|
Caliway Biopharmaceuticals Co Ltd
TWSE:6919
|
Income from Continuing Operations
-NT$351.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Nang Kuang Pharmaceutical Co Ltd
Glance View
Nang Kuang Pharmaceutical Co., Ltd. engages in the manufacture, process, and sale of western medicine and medical equipment. The company is headquartered in Tainan, Tainan. The company went IPO on 2005-06-10. The firm main products include injections, sterile injections, powder injections, hard capsules, bare ingots, film ingots, casing ingots, granules and creams, among others. The firm is also engaged in the manufacture, processing and trading of medical equipment. The firm distributes its products within the domestic market and to overseas markets.
See Also
What is Nang Kuang Pharmaceutical Co Ltd's Income from Continuing Operations?
Income from Continuing Operations
243.9m
TWD
Based on the financial report for Dec 31, 2025, Nang Kuang Pharmaceutical Co Ltd's Income from Continuing Operations amounts to 243.9m TWD.
What is Nang Kuang Pharmaceutical Co Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
6%
Over the last year, the Income from Continuing Operations growth was 0%. The average annual Income from Continuing Operations growth rates for Nang Kuang Pharmaceutical Co Ltd have been -12% over the past three years , 6% over the past five years .
